IPSEN – Buy-back programme – Art 5 of MAR – Week 39 – 2023

Back

IPSEN – Buy-back programme – Art 5 of MAR – Week 39 – 2023

- 06 October 2023 - 1 mins read

Aggregated presentation by day and by market

Name of issuerIdentification code of issuer (Legal Entity Identifier)Day of transactionIdentification code of financial instrumentAggregated daily volume (in number of shares)Daily weighted average price of the purchased shares *Market (MIC Code)
IPSEN549300M6SGDPB4Z94P1125/09/2023FR001025915084123.40AQEU
IPSEN549300M6SGDPB4Z94P1125/09/2023FR001025915032123.40CEUX
IPSEN549300M6SGDPB4Z94P1125/09/2023FR001025915038122.40TQEX
IPSEN549300M6SGDPB4Z94P1125/09/2023FR00102591501,446123.01XPAR
IPSEN549300M6SGDPB4Z94P1126/09/2023FR00102591509123.30AQEU
IPSEN549300M6SGDPB4Z94P1126/09/2023FR0010259150382123.48CEUX
IPSEN549300M6SGDPB4Z94P1126/09/2023FR001025915079123.07TQEX
IPSEN549300M6SGDPB4Z94P1126/09/2023FR00102591501,130122.94XPAR
IPSEN549300M6SGDPB4Z94P1127/09/2023FR0010259150116122.88CEUX
IPSEN549300M6SGDPB4Z94P1127/09/2023FR00102591508125.20TQEX
IPSEN549300M6SGDPB4Z94P1127/09/2023FR00102591501,476123.52XPAR
IPSEN549300M6SGDPB4Z94P1128/09/2023FR0010259150161122.38AQEU
IPSEN549300M6SGDPB4Z94P1128/09/2023FR001025915038122.50CEUX
IPSEN549300M6SGDPB4Z94P1128/09/2023FR00102591501,401122.28XPAR
IPSEN549300M6SGDPB4Z94P1129/09/2023FR001025915037125.00AQEU
IPSEN549300M6SGDPB4Z94P1129/09/2023FR0010259150302124.77CEUX
IPSEN549300M6SGDPB4Z94P1129/09/2023FR001025915061124.80TQEX
IPSEN549300M6SGDPB4Z94P1129/09/2023FR00102591501,200124.75XPAR
       
* Two-digit rounding after the decimal TOTAL8,000123.33 

Attachment

Related Press Releases

Ipsen S.A. – Formalities for making available and consulting preparatory documents to the 2024 Annual General Meeting
07 May 2024 5 mins read

Ipsen S.A. – Formalities for making available and consulting preparatory documents to the 2024 Annual General Meeting
Ipsen – Monthly information relative to the total number of voting rights and shares composing the share capital
06 May 2024 1 mins read

Ipsen – Monthly information relative to the total number of voting rights and shares composing the share capital
Ipsen delivers strong sales in the first quarter of 2024, driven by growth platforms & new medicines, and confirms its full-year guidance
24 April 2024 7 mins read

Ipsen delivers strong sales in the first quarter of 2024, driven by growth platforms & new medicines, and confirms its full-year guidance
Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases
22 April 2024 5 mins read

Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases
Ipsen publishes its 2023 Universal Registration Document
17 April 2024 4 mins read

Ipsen publishes its 2023 Universal Registration Document
Ipsen – Monthly information relative to the total number of voting rights and shares composing the share capital
08 April 2024 1 mins read

Ipsen – Monthly information relative to the total number of voting rights and shares composing the share capital
Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors
02 April 2024 7 mins read

Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors
Ipsen – Monthly information relative to the total number of voting rights and shares composing the share capital
07 March 2024 1 mins read

Ipsen – Monthly information relative to the total number of voting rights and shares composing the share capital
Ipsen S.A. publishes its 2023 Consolidated Financial Statements
15 February 2024 1 mins read

Ipsen S.A. publishes its 2023 Consolidated Financial Statements
Ipsen’s Onivyde® regimen, a potential new standard-of-care first-line therapy in metastatic pancreatic adenocarcinoma, approved by FDA  
13 February 2024 14 mins read

Ipsen’s Onivyde® regimen, a potential new standard-of-care first-line therapy in metastatic pancreatic adenocarcinoma, approved by FDA